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  Background: Success of transplantation is critically dependent upon the quality of the donor organ and optimal 
management. Recently, hormonal replacement therapy has been reported to result in rapid recovery of cardiac func-
tion and enable significantly more organs to be transplanted, while some other studies show conflicting results. The 
aim of this study is to comprehensively evaluate changes in basal circulating hormonal levels of the brain-dead or-
gan donors. 
  Methods: We reviewed the records of all brain-dead patients between January, 2004, and June, 2007. Hemodyna-
mic variables, plasma hormone levels were recorded at following time points: admission to the ICU (T1, baseline), 
30 minutes (min) after first apnea test (T2), 30 min after second apnea test (T3), before operation for harvesting 
(T4). Hormonal measurements included cortisol, adrenocorticotrophic hormone, triiodothyronine (T3), thyroxine, free 
thyroxine, thyroid-stimulating hormone, growth hormone, and testosterone. 
  Results: Nineteen patients were included in this study. Comparisons of hemodynamic parameters and hormonal 
levels to baseline values revealed no significant changes throughout the study period. When the patients were div-
ided into 2 groups according to the requirement of norepinephrine (either＞0.05 or ≤0.05μg/kg/min), patients re-
quiring ＞0.05μg/kg/min of norepinephrine had T3 level below the normal range at significantly more time points 
of measurement (7 vs. 0).
  Conclusions: In this comprehensive assessment of hormonal levels in brain-dead organ donors, we could not ob-
serve any significant changes during the ICU stay. Replacement therapy of T3 may be considered in patients requir-
ing ＞0.05μg/kg/min of norepinephrine.
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INTRODUCTION
  Despite advances in medical management strategies, trans-
plantation is still being considered as the only definitive treat-
ment for patients with end-stage cardiac, pulmonary and hep-
atic disease.1) Organ transplantations from brain-dead donors 
have increased since the first successful kidney transplantation 
in 1979 and 597 transplants were performed from 141 
brain-dead donors in 2006 in Korea. However, the demand for 
transplantable organs continues to exceed the supply. The suc-
cess of transplantation is critically dependent upon the quality 
of the donor organ and optimal management. Optimal manage-
ment of brain-dead donors is important for the maximal uti-
lization and also right timed operation, because hemodynamic 
stability is a key part of successful organ recovery. 
  A characteristic feature of brain death is the sympathetic 
storming, causing extreme hypertension and tachycardia, fol-
lowed by loss of sympathetic tone and massive vasodilatation 
leading to hemodynamic instability.2) Also, various functional 
components of the pituitary and hypothalamic regulatory sys-
tems may also become affected as ischemia spreads, resulting 
in decreased circulating levels of triiodothyronine (T3), corti-
sol/adrenocorticotrophic hormone (ACTH), insulin and arginine 
vasopressin.2-5) Recently, hormonal replacement therapy has 
been reported to result in rapid recovery of cardiac function in 
both experimental animals and humans, and to enable sig-
nificantly more organs to be transplanted,6-8) while some other 
studies show conflicting results.9,10) In this study, we inves-
tigated the hormonal changes during organ donor management 
in intensive care unit (ICU) and evaluated correlation of the 
hormonal levels with hemodynamic parameters and the amount 
of vasopressor needed to maintain blood pressure in the 
Yong Seon Choi, et al：Hormonal Changes of the Brain-Dead Organ Donors: A 3-Year Experience  31
brain-dead donors. The aim of this study is to comprehensively 
evaluate changes in basal circulating hormonal levels of the 
brain-dead organ donors. 
MATERIALS AND METHODS
  We reviewed the records of all brain-dead patients that suc-
cessfully donated organs between January, 2004, and June, 
2007. We examined donors with regard to age, sex, diagnosis, 
number of organs donated, type of organ donated, the presence 
or absence of brain-death associated complications. We adopted 
a new policy of aggressive donor management for potential or-
gan donors since January, 2004. This policy involves early 
identification of potential organ donors, admission to the surgi-
cal ICU, and management by a dedicated team using a pre-
defined protocol. The protocol for aggressive donor manage-
ment includes the following elements: (i) pulmonary artery 
catheterization to monitor hemodynamic status and tissue perfu-
sion, (ii) aggressive intravenous fluid resuscitation, (iii) vaso-
pressor infusion in case of mean arterial pressures under 70 
mmHg despite fluid resuscitation, (iv) identification of brain 
death related complications and prompt interventions. However, 
this protocol did not include hormone replacement therapy at 
that time. Neurogenic pulmonary edema was treated suppor-
tively utilizing high positive end expiratory pressure ventilation; 
diabetes insipidus was treated with fluid replacement and vaso-
pressin infusion; disseminated intravascular coagulopathy and 
thrombocytopenia were treated with blood and blood products; 
electrolyte abnormalities and acidosis were treated accordingly; 
and hypothermia was either avoided or if present treated with 
external warming methods. Dopamine was used as the primary 
vasopressor to potential donors with hemodynamic instability; 
norepinephrine was used when requirements for dopamine ex-
ceeded dosage of 10μg/kg/min. In addition, to evaluate the 
need for additional hormone-replacement therapy, high-dose 
vasopressor was defined when the dose of norepinephrine ex-
ceeded 0.05μg/kg/min. 
  Brain-death diagnosis was confirmed when an irreversible 
catastrophic structural brain lesion resulted in unresponsiveness 
to noxious pain stimuli and abolition of brainstem reflexes (pa-
pillary light responses, corneal reflexes, vestibuloocular tests, 
tracheobronchial stimulation) in the absence of hypothermia, 
metabolic or electrolyte disturbances, and depressant drugs. 
Testing for apnea was performed using guidelines after all oth-
er brain-death criteria had been fulfilled.11,12) The interval be-
tween two evaluations for diagnosis of brain death was 6 
hours when age of brain-dead donor was more than 6 years.
  Hemodynamic variables, arterial blood gas analyses and ven-
tilator mode were recorded at the following points: admission 
to the ICU (T1), 30 minutes (min) after first apnea test (T2), 
30 min after second apnea test (T3), before operation for har-
vesting (T4). Hemodynamic measurements included mean arte-
rial pressure (MAP), central venous pressure (CVP), pulmonary 
capillary wedge pressure (PCWP), and cardiac index (CI). 
Blood sampling for the hormone levels was performed at the 
same points. Hormonal measurements included cortisol, ACTH, 
growth hormone (GH), testosterone and the thyroid hormone 
levels as measured by T3, thyroxine (T4), free thyroxine (fT4) 
and thyroid-stimulating hormone (TSH). However, blood sam-
pling for cortisol and ACTH was performed twice at the 
morning of ICU day 1 and at the evening of ICU day 2; tes-
tosterone was sampled only in male patients. Determination of 
T3, T4, fT4, TSH, cortisol (sensitivity: 0.02μg/dl) and testoster-
one was performed using a chemiluminescent immunoassay 
(ADVIA Centaur, Simens, New York, USA), and Determina-
tion of ACTH (sensitivity: 1.2 pg/ml) and GH was performed 
using an immunoradiometric assay (Gamma counter COBRA 
II, Packard, Meriden, USA). Operative harvesting of the allog-
rafts generally occurred within 12 hours of the declaration of 
clinical brain death. 
  Statistical analyses were performed with SPSS 13.0 (SPSS 
Inc., Chicago, IL, USA). All data are expressed as mean±stan-
dard deviation (SD) or number of patients. Changes between 
time points within the group were compared using univariate 
analysis of variance with post hoc comparisons using the 
Dunnette's test. A p value of less than 0.05 was considered 
statistically significant.
RESULTS
  A total of 23 patients were admitted to the ICU after clin-
ical brain death during the three-year period. Four patients 
were excluded due to incomplete data collection of hormonal 
levels. The other 19 patients (14 men, 5 women), having a 
mean age of 32±13 yrs (range, 12 to 63 yrs), were included 
in this study. The cause of brain death was cerebrovascular 
disease in 11 cases (58%), cerebral anoxia related to cardiac 
arrest in 5 cases (26%), and head trauma in 3 cases (16%). 
  Comparisons of hemodynamic parameters to baseline values 
revealed no significant changes throughout the study period, 
except CVP which was significantly increased at T4 (p=0.031, 
Table 1). No significant changes in hormonal levels were ob-
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Table 1. Changes in Hemodynamic Variables and Requirement of Vasopressors
Parameters T1 T2 T3 T4
HR (beats/min)   99±24  100±18  102±20   99±19
MAP (mmHg)   89±20   93±16   86±15   88±11
PCWP (mmHg)   11±5   13±6   15±11   14±4
CVP (mmHg)    6±2    6±2    7±3    8±3*
CI (L/min/m2)  3.8±1.4  4.0±1.1  4.0±0.9  3.8±1.1
SVRI (dynesㆍsecㆍcm−5· m2) 1756±773 2066±793 1969±460 1429±276
PVRI (dynesㆍsecㆍcm−5· m2)  178±63  189±175  158±66  156±95
Dopamine (μg/kg/min)  5.9±7.8  4.6±4.2  4.8±4.1  4.1±4.4
Norepinephrine (μg/kg/min) 0.10±0.17 0.12±0.18 0.13±0.14 0.12±0.12
Values are mean±SD. T1: after admission to ICU; T2: 30 min after first certification; T3: 30 min after second certification; T4: before 
operation; HR: heart rate; MAP: mean arterial pressure; PCWP: pulmonary capillary wedge pressure; CVP: central venous pressure; CI: 
cardiac index; SVRI: systemic vascular resistance index; PVRI: pulmonary vascular resistance index. *p＜0.05 compared with T1.
Table 2. Change of Plasma Hormone Levels
T1 T2 T3 T4 Range Normal range Sensitivity
T3 (ng/ml) 0.74±0.15 0.87±0.30 0.90±0.33 0.90±0.30 0.48∼1.62  0.6∼1.8 0.1
T4 (μg/ml) 5.18±1.56 5.16±1.99 5.17±2.01 5.48±2.14 1.28∼11  4.5∼10.9 0.3
fT4 (μg/ml) 0.86±0.26 0.89±0.26 0.93±0.35 0.97±0.43  0.3∼2.18 0.89∼1.76 0.1
TSH (μIU/ml) 1.28±1.77 1.94±2.33 2.02±1.05 1.74±1.48 0.01∼8.12 0.35∼5.5 0.01
GH (ng/ml)  6.1±8.4 11.2±13.9 11.1±12.5 16.1±20.7 0.12∼77 0.1∼0.33 0.05
Testosterone (ng/dl) 62.1±35.4 79.6±64.1 75.9±67.8 65.4±55.5  10∼262 241∼827 10
Values are mean±SD. T1: after admission to ICU; T2: 30 min after first certification; T3: 30 min after second certification; T4: before 
operation; T3: triiodothyronine; T4: thyroxine; fT4: free thyroxine; TSH: thyroid-stimulating hormone; GH: growth hormone.
Table 3. Brain-Dead Donors’ Distribution according to Their Thyroid Hormone Levels 
T3 T4 fT4 TSH
Below 
normal Normal
Above 
normal
Below 
normal Normal
Above 
normal
Below 
normal Normal
Above 
normal
Below 
normal Normal
Above 
normal
T1 1 15 5 11  8  8 8  7 1
T2 1 18 8 11 10  9 7 10 2
T3 2 17 7 12  9 10 7 10 2
T4 3 16 7 12  8  9 1 5 12
Values are number of patients. T1: after admission to ICU; T2: 30 min after first certification; T3: 30 min after second certification; T4: 
before operation; T3: triiodothyronine; T4: thyroxine; fT4: free thyroxine; TSH: thyroid-stimulating hormone.
served throughout the study period compared to baseline values 
(Table 2). Concentrations of cortisol were 11.3±10.6μg/dl at 
the evening of ICU day 1 and 12.0±11.4μg/dl at the morning 
of ICU day 2. Concentrations of ACTH were 10.6±4.9 pg/ml 
at the evening of ICU day 1 and 17.3±42.0 pg/ml at the 
morning of ICU day 2. Concentration of cortisol and ACTH 
were below normal in 13 and 17 patients at the evening of ICU 
day 1, in 12 and 15 patients at the morning of ICU day 2. 
  Distributions of brain-dead donors according to their thyroid 
hormone levels at each time point are shown in Table 3. The 
number of low T3 donors was 1, 1, 2 and 3 at T1, T2, T3, 
and T4, respectively in all four patients. One of them showed 
sustained T3 level below the normal range during the study. 
Three of them showed T3 level below the normal range at T3, 
T4, and T4, respectively. To determine if there were differ-
ences in thyroid hormone levels and requirement of vaso-
pressor, all thyroid hormone values were separated according to 
the high or low dose of vasopressor regardless of time of 
blood sampling. When the patients were divided into 2 groups 
according to the requirement of norepinephrine (either ＞0.05 
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Table 4. Requirement of Vasopressors during ICU Management 
Compared with Thyroid Hormone Levels
High-dose Low-dose vasopressors
vasopressors or none
T3 
  Below normal  7  0
  Normal to high 37 29
T4 
  Below normal 17 10
  Normal to high 27 19
fT4 
  Below normal 22 13
  Normal to high 21 16
TSH 
  Below normal 17 10
  Normal to high 27 19
Values are number of data sets. T3: triiodothyronine; T4: thyro-
xine; fT4: free thyroxine; TSH: thyroid-stimulating hormone. 
or ≤0.05μg/kg/min), patients requiring ＞0.05μg/kg/min of 
norepinephrine had T3 level below the normal range at sig-
nificantly more time points of measurement. In addition, at all 
time points when the T3 levels were below the normal range, 
all of the donors required high dose vasopressors infusion 
(Table 4). The number of patients requiring high-dose vaso-
pressor was 11 (58%), 10 (53%), 12 (63%) and 12 at T1, T2, 
T3, and T4, respectively. There were no differences in the re-
quirements of dopamine between low T3 donors and normal T3 
donors. 
  There were 16 kidney and liver donors, and 3 kidney only 
donors. Also, 5 of kidney and liver donors underwent heart 
harvest; 1 underwent heart and lung harvest; 3 underwent pan-
creas harvest. The lengths of stay in the ICU and hospital 
were 2.1±0.5 days and 10.8±12.2 days, respectively. The brain 
death associated complications were coagulopathy (2 patients), 
thrombocytopenia (2 patients), cardiac ischemia (6 patients), 
acidosis (1 patient), neurogenic pulmonary edema (3 patients), 
renal failure (3 patients) and diabetes insipidus (8 patients). 
The patients used vasopressin due to diabetes insipidus were 2, 
2, 2 and 2 at T1, T2, T3, and T4, respectively. 
DISCUSSION
  In the present study, we have shown that plasma T3 level 
correlated with requirements of vasopressor during brain-dead 
donor management in ICU. Although the basal concentration of 
the anterior pituitary hormones varied considerably relative to 
the normal range, all were above the sensitivity of the assay 
in almost all cases. The concentrations of cortisol, ACTH and 
testosterone were below normal in most of our patients; the 
concentration of GH was markedly elevated and was more 
than 5 ng/ml in 59% of the cases at T2, T3 and T4. 
  Sequential systemic physiologic changes occur as different 
areas of the brain stem become ischemic. Pontine ischemia re-
sults in mixed vagal and sympathetic stimulation, characterized 
by bradycardia and hypertension; medulla ischemia results in 
unopposed sympathetic stimulation as ischemia spreads.2) The 
function of the pituitary and hypothalamic regulatory system 
may also become affected as ischemia spreads; a number of 
hormonal changes occur after brain stem death and reflect an-
terior and posterior pituitary failure. Not all these hormonal 
dysfunction are seen in every potential organ donor. The in-
cidence and severity of the derangement depends upon the eti-
ology and time course of brain stem death, and also increases 
with time after the onset of brain stem death.2) The basal hor-
mone concentrations changed insignificantly during ICU man-
agement after the clinical brain death in this study. Since the 
half-life of the anterior pituitary hormones is less than 1 
hour,13) these hormones, therefore, was undoubtedly being re-
leased until operation for harvest. The excess increase of GH 
may be related to a stress reaction or triggered by the in-
sulin-induced drop in serum glucose.14) Although anti-diuretic 
hormone (ADH) was not included in this study, brain death is 
typically accompanied by diabetes insipidus (DI) reflecting pos-
terior pituitary insufficiency. There was early depletion of 
ADH and development of DI in almost 80% of brain stem 
dead organ donors.15) In this study, there were 8 patients 
(42%) with DI and treated with continuous IV vasopressin 
infusion. 
  Several studies have highlighted hemodynamic instability, 
myocardial injury, and impairment in cardiac function after 
brain death.16-19) This cardiovascular deterioration is associated 
with impaired cellular oxygen utilization, a shift from aerobic 
to anaerobic metabolism, depletion of glycogen and myocardial 
high-energy stores, and the accumulation of lactate.20,21) This ir-
regular metabolism has been associated with low levels of T3, 
T4, and to a lesser extent cortisol and insulin.22) The etiology 
of this hypothyroid state may be a result of lower than normal 
TSH levels caused by irreversible damage to the hypothalamus 
and pituitary, as well as decreased peripheral conversion of T4 
to more potent T3. In this study, low incidence of low serum 
T3 concentration was documented in our brain-dead patients. 
Some of our patients had a decrease in circulating T4 and 
TSH concentration, whereas the serum T3 concentrations were 
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in the normal ranges in most of them. There were no differ-
ences in hemodynamics between low T3 donors and normal T3 
donors; however, we found significant correlation between low 
T3 levels and requirements of high-dose vasopressor. These re-
sults suggest that serum T3 concentration was a major determi-
nant of cardiac function in our brain-dead patients. 
  The effects of T3 administration in brain-dead patients 
sparked debate considerable and led to several studies. Several 
studies documented that no correlation with their hemodynamic 
status and lower levels of T3 in brain-dead patient.23,24) Other 
studies showed a benefit only in hemodynamically unstable 
donors.25,26) Other studies showed that T3 or T4 administration 
improved cardiovascular status, and reduced inotropic support 
and the number of donors lost cardiac instability in human 
brain-dead patients.7,27) Since most of the beneficial effects of 
T3 is cardiac function,28,29) hormonal replacement therapy in-
cluding T3 was recently recommended for donors with a left 
ventricular ejection fraction less than 45% and/or with unstable 
hemodynamics.30) Recently, Rosendale et al8) showed a sub-
stantial increase in the number of organs transplanted from do-
nors receiving three-drug (T3/T4, methylprednisolone, arginine 
vasopressin) hormone-replacement therapy in the large retro-
spective analysis of 10,292 donors. In this study, we observed 
substantial decrease in plasma hormone including cortisol, 
ACTH, T4, fT4 and TSH, and DI, reflecting depletion of 
ADH. We think that these observations will provide the foun-
dations for the efficacy and optimal timing of hormonal re-
placement therapy in our hospital. The limitation of this study 
is that the number of donors was not enough to analyze stat-
istically the correlation between low T3 donors and requirement 
of high-dose vasopressor. 
  In conclusion, we showed substantial decrease in cortisol, 
ACTH, T4, fT4 and TSH, and significant correlation between 
T3 concentrations and vasopressor support in brain-dead 
patients. The addition of hormone therapy in association with 
an aggressive donor management protocol may help reduce 
vasopressor support, moreover, maximize the number of organs 
retrieved from hemodynamically unstable donors. In a time 
when the transplant waiting list is increasing more than the 
number of donors, hormonal replacement therapy may be in-
tegrated in the management of brain-dead organ donors in 
ICU. 
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